Drug intelligence / Profile preview

CDD-2105

Development stage: Phase 2
Lead developer: Centre for Chinese Herbal Medicine Drug Development
Administration: Oral

Overview

**CDD-2105** is an investigational multi-component Chinese herbal medicine formula developed for constipation-predominant irritable bowel syndrome. The granule formulation contains a traditional Chinese medicine composition comprising *Corydalis Rhizoma*, *Paeoniae Radix*, *Magnoliae Officinalis Cortex*, and *Sennae Folium*. It is being evaluated for potential relief of constipation and abdominal pain in irritable bowel syndrome with constipation; its specific molecular targets and pharmacologic mechanism have not been publicly defined.

Beyond the preview

Go deeper on CDD-2105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDD-2105.

Explore the full profile